Phase 1 study of infusional or bolus deflexifol (a novel formulation of 5FU, folinic acid, and cyclodextrin) after failure of standard treatment.

Citation

• Clingan, P. R., Ackland, S. P., Ranson, M., De Souza, P., Tafreshi, A., Aghmesheh, M., . . . Jokela, R. (2017). Phase 1 study of infusional or bolus deflexifol (a novel formulation of 5FU, folinic acid, and cyclodextrin) after failure of standard treatment.. Journal of Clinical Oncology, 35(4_suppl), tps812. doi:10.1200/jco.2017.35.4_suppl.tps812

Digital Object Identifier (doi)

• 10.1200/jco.2017.35.4_suppl.tps812

Web Of Science Accession Number

Start Page

• tps812

End Page

• tps812

Volume

• 35

Issue

• 4_suppl

Abstract

UOW Authors

•   Aghmesheh, Morteza (external author)
•   Brungs, Daniel
•   Clingan, Phillip (external author)
•   De Souza, Paul (external author)
•   Ranson, Marie

Publication Date

• 2017

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Clingan, P. R., Ackland, S. P., Ranson, M., De Souza, P., Tafreshi, A., Aghmesheh, M., . . . Jokela, R. (2017). Phase 1 study of infusional or bolus deflexifol (a novel formulation of 5FU, folinic acid, and cyclodextrin) after failure of standard treatment.. Journal of Clinical Oncology, 35(4_suppl), tps812. doi:10.1200/jco.2017.35.4_suppl.tps812

Digital Object Identifier (doi)

• 10.1200/jco.2017.35.4_suppl.tps812

Web Of Science Accession Number

Start Page

• tps812

End Page

• tps812

Volume

• 35

Issue

• 4_suppl